Rhythm Pharmaceuticals Important Notice | --- | --- | |-------|------------------| | | | | | | | | | | | | | | | | | | | | | | | David Meeker, MD | | | | | | | | 4 | ! Rhythm® | Global commercial strategy execution • >100 reimbursement approvals David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of Int ...

Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care and precision medicines addressing the root cause Forward Looking Statements ® ✓ Granted EC marketing authorization for IMCIVREE for BBS; received early access authorization in France ✓ Completed enrollment in Phase 3 trial in pediatric patients ✓ Entered non-dilutive RIFA agreement with HealthCare Royalty for up to $100 million Phase 3 weekly formul ...

Rhythm Pharmaceuticals Third Quarter 2022 Financial Results and Business Update November 8, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of International Hunter Smith, Chief Financial Officer ® 2 Forward Looking Statement ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Dae Gon - Stifel Corinne Je ...

Rhythm Pharmaceuticals Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care and precision medicines addressing the root cause September 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2022 Results Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Yann Mazabraud - Executive Vice President, Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen and Company Derek Archila - Wells ...

Rhythm Pharmaceuticals Second Quarter 2022 Financial Results and Business Update August 2, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. On Today's Call David Connolly, Executive Director of Investor Relations and Corporate Communications David Meeker, MD, Chair, President and Chief Executive Officer Jennifer Chien, Executive Vice President, Head of North America Yann Mazabraud, Executive Vice President, Head of International Hunter Smith, Chief Financial Officer ® 2 Forward Looking Statements ...

Rhythm Pharmaceuticals First Quarter 2022 Financial Results and Business Update May 3, 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements ® 2 This presentation contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including without limitations statements regarding the potential, safety, ef ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chair, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Linda Shapiro - Chief Medical Officer Hunter Smith - Chief Financial Officer Yann Mazabraud - Executive Vice President, Head of International Conference Call Participants Derek Archila - Wells Fargo Jos ...

Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity April 2022 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward Looking Statements 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical prog ...